Tebotelimab, a PD1/LAG-3 bispecific antibody, in patients with untreated, unresectable, recurrent or metastatic, mucosal melanoma: An open-label, single-arm, Phase 1 study

被引：0
|
作者：
Lu, Si
Chen, Yu
Fang, Meiyu
Zou, Zhengyun
Wu, Di
Luo, Zhiguo
Zhang, Jian
Chen, Jing
Huang, Gang
Pan, Hongming
Ren, Xiubao
Cheng, Ying
Su, Haichuan
Xin, Yuan
Hua, Qiong
Hou, Jianmei
Guo, Jun
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT208
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT208
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
    Zimmer, Lisa
    Eigentler, Thomas K.
    Kiecker, Felix
    Simon, Jan
    Utikal, Jochen
    Mohr, Peter
    Berking, Carola
    Kaempgen, Eckhart
    Dippel, Edgar
    Stadler, Rudolf
    Hauschild, Axel
    Fluck, Michael
    Terheyden, Patrick
    Rompel, Rainer
    Loquai, Carmen
    Assi, Zeinab
    Garbe, Claus
    Schadendorf, Dirk
    JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [22] Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma
    Lisa Zimmer
    Thomas K. Eigentler
    Felix Kiecker
    Jan Simon
    Jochen Utikal
    Peter Mohr
    Carola Berking
    Eckhart Kämpgen
    Edgar Dippel
    Rudolf Stadler
    Axel Hauschild
    Michael Fluck
    Patrick Terheyden
    Rainer Rompel
    Carmen Loquai
    Zeinab Assi
    Claus Garbe
    Dirk Schadendorf
    Journal of Translational Medicine, 13
  • [23] Efficacy and safety of enlonstobart (SG001), a PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer: A multicenter, single-arm, open-label, phase II study
    Zuo, Jin
    Wu, Lingying
    Li, Xiaofan
    Feng, Mei
    Li, Guiling
    Yin, Rutie
    Li, Xiumin
    Kang, Shan
    Sun, Hongmei
    Wei, Shuqing
    Zhang, Yunyan
    Wang, Yili
    Liu, Hu
    Wang, Wei
    Sun, Li
    Zhu, Zhitu
    Lin, Daren
    Jiang, Kui
    Xiang, Silong
    Niu, Miao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] A PHASE 1 EVALUATION OF TEBOTELIMAB, A BISPECIFIC PD-1 X LAG-3 DART® MOLECULE, IN COMBINATION WITH MARGETUXIMAB IN PATIENTS WITH ADVANCED HER2+NEOPLASMS
    Patel, Manish
    Luke, Jason
    Hamilton, Erika
    Chmielowski, Bartosz
    Blumenschein, George
    Kindler, Hedy
    Bahadur, Shakeela
    Santa-Maria, Cesar
    Koucheki, Janine
    Sun, Jichao
    Kaul, Sanjeev
    Chen, Francine
    Zhang, Xiaoyu
    Muth, John
    Kaminker, Patrick
    Moore, Paul
    Sumrow, Bradley
    Ulahannan, Susanna
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A193 - A193
  • [25] Teclistamab, a B-cell maturation antigenxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
    Usmani, Saad Z.
    Garfall, Alfred L.
    van de Donk, Niels W. C. J.
    Nahi, Hareth
    San-Miguel, Jesus F.
    Oriol, Albert
    Rosinol, Laura
    Chari, Ajai
    Bhutani, Manisha
    Karlin, Lionel
    Benboubker, Lotfi
    Pei, Lixia
    Verona, Raluca
    Girgis, Suzette
    Stephenson, Tara
    Elsayed, Yusri
    Infante, Jeffrey
    Goldberg, Jenna D.
    Banerjee, Arnob
    Mateos, Maria-Victoria
    Krishnan, Amrita
    LANCET, 2021, 398 (10301): : 665 - 674
  • [26] Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
    Zhang, Qiyi
    Liu, Xingyu
    Wei, Shumei
    Zhang, Lufei
    Tian, Yang
    Gao, Zhenzhen
    Jin, Ming
    Yan, Sheng
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [27] Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
    Di Giacomo, Anna Maria
    Ascierto, Paolo A.
    Pilla, Lorenzo
    Santinami, Mario
    Ferrucci, Pier Francesco
    Giannarelli, Diana
    Marasco, Antonella
    Rivoltini, Licia
    Simeone, Ester
    Nicoletti, Stefania V. L.
    Fonsatti, Ester
    Annesi, Diego
    Queirolo, Paola
    Testori, Alessandro
    Ridolfi, Ruggero
    Parmiani, Giorgio
    Maio, Michele
    LANCET ONCOLOGY, 2012, 13 (09): : 879 - 886
  • [28] ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study
    Zager, Jonathan S.
    Orloff, Marlana
    Ferrucci, Pier Francesco
    Choi, Junsung
    Eschelman, David J.
    Glazer, Evan S.
    Ejaz, Aslam
    Howard, J. Harrison
    Richtig, Erika
    Ochsenreither, Sebastian
    Reddy, Sunil A.
    Lowe, Michael C.
    Beasley, Georgia M.
    Gesierich, Anja
    Bender, Armin
    Gschnell, Martin
    Dummer, Reinhard
    Rivoire, Michel
    Arance, Ana
    Fenwick, Stephen William
    Sacco, Joseph J.
    Haferkamp, Sebastian
    Weishaupt, Carsten
    John, Johnny
    Wheater, Matthew
    Ottensmeier, Christian H.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (08) : 5220 - 5221
  • [29] A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Wang, Jie
    Asch, Adam S.
    Hamad, Nada
    Weickhardt, Andrew
    Tomaszewska-Kiecana, Monika
    Dlugosz-Danecka, Monika
    Pylypenko, Halyna
    Bahadur, Shakeela
    Ulahannan, Susanna
    Koucheki, Janine
    Sun, Jichao
    Li, Hua
    Chen, Francine
    Zhang, Xiaoyu
    Muth, John
    Kaminker, Patrick
    Moore, Paul
    Sumrow, Bradley James
    BLOOD, 2020, 136
  • [30] TORIPALIMAB PLUS CHEMORADIOTHERAPY IN PATIENTS WITH RECURRENT OR METASTATIC CERVICAL CANCER: A MULTICENTER, OPEN-LABEL, SINGLE-ARM, PHASE II TRIAL
    Xu, Xiaoting
    Huan, Jian
    Miao, Hui
    Wang, Hao
    Wang, Yue
    Zhu, Hongyu
    Jiang, Jun
    Zhou, Juying
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A384 - A384
12345